According to a new report, the UK is ahead compared to the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS. The first annual report into clinical trials created by the Association of the British Pharmaceutical Industry (ABPI), stated that the UK is a
The Association of the British Pharmaceutical Industry (ABPI) amended their guidelines on Phase I trials on Tuesday to echo alterations in the UK’s regulatory framework since the previous guidelines were issued in 2007. Since 2007, the association notes that “a considerable amount of what previously constituted guidance has now become requirement.” The updated guidelines are
Clinical Professionals will be attending the ABPI Conference on Thursday, at the Lancaster, London. The conference is called ‘can we afford innovation in medicine?’ Throughout the day innovation’s significance to the future of pharma will be examined in various keynote speeches, panel discussions and workshops. The ABPI represents research-based biopharmaceutical companies of all sizes. The
The reactions from AstraZeneca’s announcement earlier this week that approximately 7,300 jobs would be cut by the end of 2014 has continued, and it appears that the organisation’s UK research staff will be reduced by between 250 and 350 positions. AstraZeneca, the UK’s second biggest drugs maker, currently employs around 61,000 people globally, 8,000 of
The UK could be a centre for pharmaceutical innovation but the industry first must collaborate, pharmaceuticals have been told. The dominant theme at the recent ABPI (Association of the British Pharmaceutical Industry) conference was regarding driving innovation and collaboration, both of which are viewed as critical to the future success of the industry, the efficiency
The ABPI Annual Conference and Dinner 2011 will take place on Wednesday 25 May, 2011 at The Lancaster, London W2. This year the conference will be firmly focusing on the changed NHS landscape and the new ways in which the industry will need to position, price and promote its vital contribution to UK healthcare. Please use
